PDE5 inhibitors and male reproduction: Is there a place for PDE5 inhibitors in infertility clinics or andrology laboratories?
Male
Humans
Phosphodiesterase 5 Inhibitors
/ pharmacology
Sildenafil Citrate
/ therapeutic use
Vardenafil Dihydrochloride
/ therapeutic use
Andrology
Fertility Clinics
Laboratories
Sulfones
/ pharmacology
Sperm Motility
Piperazines
/ therapeutic use
Purines
/ therapeutic use
Semen
Infertility, Male
/ drug therapy
Reproduction
PDE
PDE5 inhibitors
epididymis
prostate
testis
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
27
01
2022
accepted:
24
08
2022
pubmed:
5
10
2022
medline:
20
12
2022
entrez:
4
10
2022
Statut:
ppublish
Résumé
The objective of this review study is to evaluate the therapeutic role of PDE5 inhibitors (PDE5is) in the amelioration of oligoasthenospermia in infertile males. PDE5is have a beneficial influence on the secretory function of the Leydig and Sertoli cells, the biochemical environment within the seminiferous tubule, the contractility of the testicular tunica albuginea, and the prostatic secretory function. In several studies, the overall effect of sildenafil and vardenafil increased quantitative and qualitative sperm motility. Furthermore, some studies indicate that PDE5is influence positively the sperm capacity to undergo capacitation under biochemical conditions that are known to induce the sperm capacitation process. Additional research efforts are necessary in order to recommend unequivocally the usage of sildenafil, vardenafil, or avanafil for the alleviation of male infertility.
Substances chimiques
Phosphodiesterase 5 Inhibitors
0
Sildenafil Citrate
BW9B0ZE037
Vardenafil Dihydrochloride
5O8R96XMH7
Sulfones
0
Piperazines
0
Purines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1405-1418Informations de copyright
© 2022 The Japanese Urological Association.
Références
Salonia ACB, J. Carvalho, G. Corona, T.H. Jones, A. Kadioǧlu, J.I. Martinez-Salamanca, S. Minhas, E.C. Serefoǧlu, P. Verze members of the EAU Sexual and Reproductive Health Guidelines Panel. EAU guidelines on sexual and reproductive health. Arnhem: EAU Guidelines Office; 2022.
Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58:488-520.
Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science. 2002;295:1711-5.
Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802-13.
Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002;136:515-22.
Ghofrani HA, Olschewski H, Seeger W, Grimminger F. Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure. Pneumologie. 2002;56:665-72.
Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2003;167:1139-41.
Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004;169:39-45.
Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-57.
Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi SI, Okumura K, et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem. 1999;274:18438-45.
Scipioni A, Stefanini S, Santone R, Giorgi M. Immunohistochemical localisation of PDE5 in Leydig and myoid cells of prepuberal and adult rat testis. Histochem Cell Biol. 2005;124:401-7.
Djoseland O, Gordeladze JO, Hoglo S, Halse JI, Haugen HN. Evidence for androgen-dependent phosphodiesterase activity in rat seminal vesicle and epididymis. Int J Androl. 1980;3:363-6.
Benau D, Szabo EI, Terner C. Endogenous inhibitors of cyclic adenosine 3′,5′-monophosphate-phosphodiesterase in rat epididymis. Biol Reprod. 1986;35:799-805.
Razzaboni B, Terner C. Cyclic adenosine 3′,5′-monophosphate-phosphodiesterases in epididymis and prostate of castrate and of aged rats. Mech Ageing Dev. 1988;43:61-9.
Setchell BP, Maddocks S, Brooks DE. Anatomy, vasculature, innervation, and fluids of the male reproductive tract. In: Knobil E, Neill JD, editors. The physiology of reproduction. New York: Raven Press; 1994. p. 1063-175.
Zhang C, Yeh S, Chen YT, Wu CC, Chuang KH, Lin HY, et al. Oligozoospermia with normal fertility in male mice lacking the androgen receptor in testis peritubular myoid cells. Proc Natl Acad Sci U S A. 2006;103:17718-23.
Davidoff MS, Breucker H, Holstein AF, Seidl K. Cellular architecture of the lamina propria of human seminiferous tubules. Cell Tissue Res. 1990;262:253-61.
Mewe M, Bauer CK, Muller D, Middendorff R. Regulation of spontaneous contractile activity in the bovine epididymal duct by cyclic guanosine 5′-monophosphate-dependent pathways. Endocrinology. 2006;147:2051-62.
Swinnen JV, Joseph DR, Conti M. Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes. Proc Natl Acad Sci U S A. 1989;86:5325-9.
Geremia R, Rossi P, Pezzotti R, Conti M. Cyclic nucleotide phosphodiesterase in developing rat testis. Identification of somatic and germ-cell forms. Mol Cell Endocrinol. 1982;28:37-53.
Morena AR, Boitani C, de Grossi S, Stefanini M, Conti M. Stage and cell-specific expression of the adenosine 3′,5′ monophosphate-phosphodiesterase genes in the rat seminiferous epithelium. Endocrinology. 1995;136:687-95.
Sette C, Iona S, Conti M. The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J Biol Chem. 1994;269:9245-52.
Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem. 2006;54:1205-13.
Soderling SH, Bayuga SJ, Beavo JA. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci U S A. 1998;95:8991-6.
Fujishige K, Kotera J, Omori K. Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem. 1999;266:1118-27.
Baxendale RW, Fraser LR. Mammalian sperm phosphodiesterases and their involvement in receptor-mediated cell signaling important for capacitation. Mol Reprod Dev. 2005;71:495-508.
Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology. 2006;51:374-85.
Francis SH. Phosphodiesterase 11 (PDE11): is it a player in human testicular function? Int J Impot Res. 2005;17:467-8.
Wayman C, Phillips S, Lunny C, Webb T, Fawcett L, Baxendale R, et al. Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology. Int J Impot Res. 2005;17:216-23.
Tzortzis V, Mitrakas L, Gravas S, Mamoulakis C, Meissner A, Kyriakou D, et al. Oral phosphodiesterase type 5 inhibitors alleviate recurrent priapism complicating thalassemia intermedia: a case report. J Sex Med. 2009;6:2068-71.
Georgiadis G, Zisis IE, Docea AO, Tsarouhas K, Fragkiadoulaki I, Mavridis C, et al. Current concepts on the Reno-protective effects of phosphodiesterase 5 inhibitors in acute kidney injury: systematic search and review. J Clin Med. 2020;9(5):1284.
Iordache AM, Buga AM, Albulescu D, Vasile RC, Mitrut R, Georgiadis G, et al. Phosphodiesterase-5 inhibitors ameliorate structural kidney damage in a rat model of contrast-induced nephropathy. Food Chem Toxicol. 2020;143:111535.
Iordache AM, Docea AO, Buga AM, Zlatian O, Ciurea ME, Rogoveanu OC, et al. Sildenafil and tadalafil reduce the risk of contrast-induced nephropathy by modulating the oxidant/antioxidant balance in a murine model. Food Chem Toxicol. 2020;135:111038.
Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, Heretis I, Wilks MF, Spandidos DA, et al. Contrast-induced nephropathy: basic concepts, pathophysiological implications and prevention strategies. Pharmacol Ther. 2017;180:99-112.
Maekawa M, Kamimura K, Nagano T. Peritubular myoid cells in the testis: their structure and function. Arch Histol Cytol. 1996;59:1-13.
Sofikitis N, Kaltsas A, Dimitriadis F, Rassweiler J, Grivas N, Zachariou A, et al. The effect of PDE5 inhibitors on the male reproductive tract. Curr Pharm Des. 2021;27:2697-713.
Tsounapi P, Honda M, Dimitriadis F, Koukos S, Hikita K, Zachariou A, et al. Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: a randomised controlled trial. Andrologia. 2018;50:e13071.
Dimitriadis F, Tsambalas S, Tsounapi P, Kawamura H, Vlachopoulou E, Haliasos N, et al. Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU Int. 2010;106:1181-5.
Dimitriadis F, Tsampalas S, Tsounapi P, Giannakis D, Chaliasos N, Baltogiannis D, et al. Effects of phosphodiesterase-5 inhibitor vardenafil on testicular androgen-binding protein secretion, the maintenance of foci of advanced spermatogenesis and the sperm fertilising capacity in azoospermic men. Andrologia. 2012;44(Suppl 1):144-53.
Middendorff R, Muller D, Mewe M, Mukhopadhyay AK, Holstein AF, Davidoff MS. The tunica albuginea of the human testis is characterized by complex contraction and relaxation activities regulated by cyclic GMP. J Clin Endocrinol Metab. 2002;87:3486-99.
Muller D, Mukhopadhyay AK, Speth RC, Guidone G, Potthast R, Potter LR, et al. Spatiotemporal regulation of the two atrial natriuretic peptide receptors in testis. Endocrinology. 2004;145:1392-401.
Yuasa K, Omori K, Yanaka N. Binding and phosphorylation of a novel male germ cell-specific cGMP-dependent protein kinase-anchoring protein by cGMP-dependent protein kinase Ialpha. J Biol Chem. 2000;275:4897-905.
Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci U S A. 2001;98:2703-6.
Lelievre V, Pineau N, Hu Z, Ioffe Y, Byun JY, Muller JM, et al. Proliferative actions of natriuretic peptides on neuroblastoma cells. Involvement of guanylyl cyclase and non-guanylyl cyclase pathways. J Biol Chem. 2001;276:43668-76.
Silberbach M, Roberts CT Jr. Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. Cell Signal. 2001;13:221-31.
Cameron VA, Ellmers LJ. Minireview: natriuretic peptides during development of the fetal heart and circulation. Endocrinology. 2003;144:2191-4.
Anderson RA Jr, Feathergill KA, Rawlins RG, Mack SR, Zaneveld LJ. Atrial natriuretic peptide: a chemoattractant of human spermatozoa by a guanylate cyclase-dependent pathway. Mol Reprod Dev. 1995;40:371-8.
Rotem R, Zamir N, Keynan N, Barkan D, Breitbart H, Naor Z. Atrial natriuretic peptide induces acrosomal exocytosis of human spermatozoa. Am J Physiol. 1998;274:E218-23.
Middendorff R, Davidoff MS, Behrends S, Mewe M, Miethens A, Muller D. Multiple roles of the messenger molecule cGMP in testicular function. Andrologia. 2000;32:55-9.
Middendorff R, Muller D, Paust HJ, Davidoff MS, Mukhopadhyay AK. Natriuretic peptides in the human testis: evidence for a potential role of C-type natriuretic peptide in Leydig cells. J Clin Endocrinol Metab. 1996;81:4324-8.
Middendorff R, Kumm M, Davidoff MS, Holstein AF, Muller D. Generation of cyclic guanosine monophosphate by heme oxygenases in the human testis-a regulatory role for carbon monoxide in Sertoli cells? Biol Reprod. 2000;63:651-7.
Middendorff R, Muller D, Wichers S, Holstein AF, Davidoff MS. Evidence for production and functional activity of nitric oxide in seminiferous tubules and blood vessels of the human testis. J Clin Endocrinol Metab. 1997;82:4154-61.
Eskild W, Hansson V. Vitamin A functions in the reproductive organs. In: Blomhoff R, editor. Vitamin A in health and disease. New York: Marcel Dekker, Inc.; 1994. p. 531-59.
Dimitriadis F, Giannakis D, Pardalidis N, Zikopoulos K, Paraskevaidis E, Giotitsas N, et al. Effects of phosphodiesterase-5 inhibitors on sperm parameters and fertilizing capacity. Asian J Androl. 2008;10:115-33.
Dimitriadis F, Tsiriopoulos I, Baltogiannis D, Tsounapi P, Gratsias S, Vlachopoulou E, et al. Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function. 24th annual EUA congress. March 17th-21st 2009, Stockholm. Eur Urol Suppl. 2009;8(4):215.
Saez JM. Leydig cells: endocrine, paracrine, and autocrine regulation. Endocr Rev. 1994;15:574-626.
Stocco DM, Wang X, Jo Y, Manna PR. Multiple signaling pathways regulating steroidogenesis and steroidogenic acute regulatory protein expression: more complicated than we thought. Mol Endocrinol. 2005;19:2647-59.
Catt KJ, Dufau ML. Spare gonadotrophin receptors in rat testis. Nat New Biol. 1973;244:219-21.
Mendelson C, Dufau M, Catt K. Gonadotropin binding and stimulation of cyclic adenosine 3′:5′-monophosphate and testosterone production in isolated Leydig cells. J Biol Chem. 1975;250:8818-23.
Vasta V, Shimizu-Albergine M, Beavo JA. Modulation of Leydig cell function by cyclic nucleotide phosphodiesterase 8A. Proc Natl Acad Sci U S A. 2006;103:19925-30.
Glavas NA, Ostenson C, Schaefer JB, Vasta V, Beavo JA. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci U S A. 2001;98:6319-24.
Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun. 1998;246:570-7.
Vlachopoulou E, Tsiriopoulos I, Dimitriadis F, Baltogiannis D, Miyagawa I, Sofikitis N. Effects of vardenafil on Sertoli cell secretory function. 24th annual EUA congress. March 17th-21st 2009, Stockholm. Eur Urol Suppl. 2009;8(4):148.
Conti M, Toscano MV, Petrelli L, Geremia R, Stefanini M. Regulation of follicle-stimulating hormone and dibutyryl adenosine 3′,5′-monophosphate of a phosphodiesterase isoenzyme of the Sertoli cell. Endocrinology. 1982;110:1189-96.
Rossi P, Pezzotti R, Conti M, Geremia R. Cyclic nucleotide phosphodiesterases in somatic and germ cells of mouse seminiferous tubules. J Reprod Fertil. 1985;74:317-27.
Conti M, Iona S, Cuomo M, Swinnen JV, Odeh J, Svoboda ME. Characterization of a hormone-inducible, high affinity adenosine 3′-5′-cyclic monophosphate phosphodiesterase from the rat Sertoli cell. Biochemistry. 1995;34:7979-87.
Zhao AZ, Yan C, Sonnenburg WK, Beavo JA. Recent advances in the study of Ca2+/CaM-activated phosphodiesterases: expression and physiological functions. Adv Second Messenger Phosphoprotein Res. 1997;31:237-51.
Baxendale R, Burslem F, Phillips S. Phosphodiesterase type 11 (PDE11) cellular localisation: progress towards defining a physiological role in testis and/or reproduction. J Urol. 2001;165(suppl 5):340.
Yan C, Zhao AZ, Sonnenburg WK, Beavo JA. Stage and cell-specific expression of calmodulin-dependent phosphodiesterases in mouse testis. Biol Reprod. 2001;64:1746-54.
Salanova M, Chun SY, Iona S, Puri C, Stefanini M, Conti M. Type 4 cyclic adenosine monophosphate-specific phosphodiesterases are expressed in discrete subcellular compartments during rat spermiogenesis. Endocrinology. 1999;140:2297-306.
Farooqui SM, Al-Bagdadi F, Houslay MD, Bolger GB, Stout R, Specian RD, et al. Surgically induced cryptorchidism-related degenerative changes in spermatogonia are associated with loss of cyclic adenosine monophosphate-dependent phosphodiesterases type 4 in abdominal testes of rats. Biol Reprod. 2001;64:1583-9.
Ricker DD. The autonomic innervation of the epididymis: its effects on epididymal function and fertility. J Androl. 1998;19:1-4.
Mewe M, Bauer CK, Schwarz JR, Middendorff R. Mechanisms regulating spontaneous contractions in the bovine epididymal duct. Biol Reprod. 2006;75:651-9.
Mulryan K, Gitterman DP, Lewis CJ, Vial C, Leckie BJ, Cobb AL, et al. Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature. 2000;403:86-9.
Tamura N, Doolittle LK, Hammer RE, Shelton JM, Richardson JA, Garbers DL. Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc Natl Acad Sci U S A. 2004;101:17300-5.
Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52:375-414.
Abdel-Hamid IA. Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action. Drugs. 2004;64:13-26.
Chen J, Mabjeesh NJ, Matzkin H, Greenstein A. Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology. 2003;61:197-200.
Birowo P, Uckert S, Kedia GT, Sonnenberg JE, Sandner P, Thon WF, et al. Exposure of human seminal vesicle tissue to phosphodiesterase (PDE) inhibitors antagonizes the contraction induced by norepinephrine and increases production of cyclic nucleotides. Urology. 2010;76(1518):e1-6.
La Vignera S. Seminal vesicles of infertile patients with male accessory gland infection: ultrasound evaluation after prolonged treatment with tadalafil, a selective phosphodiesterase-5 inhibitor. Andrologia. 2013;45:386-91.
Tsounapi P, Honda M, Dimitriadis F, Kawamoto B, Hikita K, Muraoka K, et al. Impact of antioxidants on seminal vesicles function and fertilizing potential in diabetic rats. Asian J Androl. 2017;19:639-46.
Ponchietti R, Raugei A, Lanciotti E, Ademollo B, Galvan P, Poggini G. Calcium, zinc, magnesium, concentration in seminal plasma of infertile men with prostatitis. Acta Eur Fertil. 1984;15:283-5.
Sofikitis NV, Miyagawa I. Endocrinological, biophysical, and biochemical parameters of semen collected via masturbation versus sexual intercourse. J Androl. 1993;14:366-73.
Fair WR, Couch J, Wehner N. The purification and assay of the prostatic antibacterial factor (PAF). Biochem Med. 1973;8:329-39.
Meares EM Jr. Prostatitis. Med Clin North Am. 1991;75:405-24.
Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H, et al. Characterization and localization of nitric oxide synthase in the human prostate. Urology. 1995;45:435-9.
Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology. 1995;45:440-6.
Morelli G, Pagni R, Mariani C, Minervini R, Morelli A, Gori F, et al. Results of vardenafil mediated power doppler ultrasound, contrast enhanced ultrasound and systematic random biopsies to detect prostate cancer. J Urol. 2011;185:2126-31.
Oger S, Behr-Roussel D, Gorny D, Lebret T, Denoux Y, Alexandre L, et al. Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. Eur Urol. 2010;57:699-707.
Fisch JD, Behr B, Conti M. Enhancement of motility and acrosome reaction in human spermatozoa: differential activation by type-specific phosphodiesterase inhibitors. Hum Reprod. 1998;13:1248-54.
Sikka SC, Hellstrom WJ. The application of pentoxifylline in the stimulation of sperm motion in men undergoing electroejaculation. J Androl. 1991;12:165-70.
Tesarik J, Thebault A, Testart J. Effect of pentoxifylline on sperm movement characteristics in normozoospermic and asthenozoospermic specimens. Hum Reprod. 1992;7:1257-63.
Tournaye H, Devroey P, Camus M, Van der Linden M, Janssens R, Van Steirteghem A. Use of pentoxifylline in assisted reproductive technology. Hum Reprod. 1995;10(Suppl 1):72-9.
Haesungcharern A, Chulavatnatol M. Stimulation of human spermatozoal motility by caffeine. Fertil Steril. 1973;24:662-5.
Schill WB. Caffeine- and kallikrein-induced stimulation of human sperm motility: a comparative study. Andrologia. 1975;7:229-36.
De Turner E, Aparicio NJ, Turner D, Schwarzstein L. Effect of two phosphodiesterase inhibitors, cyclic adenosine 3′:5′-monophosphate, and a beta-blocking agent on human sperm motility. Fertil Steril. 1978;29:328-31.
Schill WB, Pritsch W, Preissler G. Effect of caffeine and kallikrein on cryo-preserved human spermatozoa. Int J Fertil. 1979;24:27-32.
Marrama P, Baraghini GF, Carani C, Celani MF, Giovenco P, Grandi F, et al. Further studies on the effects of pentoxifylline on sperm count and sperm motility in patients with idiopathic oligo-asthenozoospermia. Andrologia. 1985;17:612-6.
Yovich JM, Edirisinghe WR, Cummins JM, Yovich JL. Preliminary results using pentoxifylline in a pronuclear stage tubal transfer (PROST) program for severe male factor infertility. Fertil Steril. 1988;50:179-81.
Yovich JM, Edirisinghe WR, Cummins JM, Yovich JL. Influence of pentoxifylline in severe male factor infertility. Fertil Steril. 1990;53:715-22.
Shen MR, Chiang PH, Yang RC, Hong CY, Chen SS. Pentoxifylline stimulates human sperm motility both in vitro and after oral therapy. Br J Clin Pharmacol. 1991;31:711-4.
Fuse H, Sakamoto M, Ohta S, Katayama T. Effect of pentoxifylline on sperm motion. Arch Androl. 1993;31:9-15.
Pang SC, Chan PJ, Lu A. Effects of pentoxifylline on sperm motility and hyperactivation in normozoospermic and normokinetic semen. Fertil Steril. 1993;60:336-43.
Tasdemir M, Tasdemir I, Kodama H, Tanaka T. Pentoxifylline-enhanced acrosome reaction correlates with fertilization in vitro. Hum Reprod. 1993;8:2102-7.
Tournaye H, Van Steirteghem AC, Devroey P. Pentoxifylline in idiopathic male-factor infertility: a review of its therapeutic efficacy after oral administration. Hum Reprod. 1994;9:996-1000.
Yunes R, Fernandez P, Doncel GF, Acosta AA. Cyclic nucleotide phosphodiesterase inhibition increases tyrosine phosphorylation and hyper motility in normal and pathological human spermatozoa. Biocell. 2005;29:287-93.
Wang C, Chan CW, Wong KK, Yeung KK. Comparison of the effectiveness of placebo, clomiphene citrate, mesterolone, pentoxifylline, and testosterone rebound therapy for the treatment of idiopathic oligospermia. Fertil Steril. 1983;40:358-65.
Lopes S, Jurisicova A, Sun JG, Casper RF. Reactive oxygen species: potential cause for DNA fragmentation in human spermatozoa. Hum Reprod. 1998;13:896-900.
Twigg J, Fulton N, Gomez E, Irvine DS, Aitken RJ. Analysis of the impact of intracellular reactive oxygen species generation on the structural and functional integrity of human spermatozoa: lipid peroxidation, DNA fragmentation and effectiveness of antioxidants. Hum Reprod. 1998;13:1429-36.
Purvis K, Muirhead GJ, Harness JA. The effects of sildenafil on human sperm function in healthy volunteers. Br J Clin Pharmacol. 2002;53(Suppl 1):53S-60S.
Jannini EA, Lombardo F, Salacone P, Gandini L, Lenzi A. Treatment of sexual dysfunctions secondary to male infertility with sildenafil citrate. Fertil Steril. 2004;81:705-7.
Lenzi A, Lombardo F, Salacone P, Gandini L, Jannini EA. Stress, sexual dysfunctions, and male infertility. J Endocrinol Invest. 2003;26:72-6.
du Plessis SS, de Jongh PS, Franken DR. Effect of acute in vivo sildenafil citrate and in vitro 8-bromo-cGMP treatments on semen parameters and sperm function. Fertil Steril. 2004;81:1026-33.
Sofikitis N, Miyagawa I. Secretory dysfunction of the male accessory genital glands due to prostatic infections and fertility; a selected review of the literature. Jpn J Fertil Steril. 1991;36:690-9.
Portnoy L. The diagnosis and prognosis of male infertility: a study of 44 cases with special reference to sperm morphology. J Urol. 1946;48:735-46.
Ali ST, Rakkah NI. Neurophysiological role of sildenafil citrate (Viagra) on seminal parameters in diabetic males with and without neuropathy. Pak J Pharm Sci. 2007;20:36-42.
Pomara G, Morelli G, Canale D, Turchi P, Caglieresi C, Moschini C, et al. Alterations in sperm motility after acute oral administration of sildenafil or tadalafil in young, infertile men. Fertil Steril. 2007;88:860-5.
Hellstrom WJ, Gittelman M, Jarow J, Steidle C, McMurray J, Talley D, et al. An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. Eur Urol. 2008;53:1058-65.
Hellstrom WJ, Overstreet JW, Yu A, Saikali K, Shen WE, Beasley CM, et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol. 2003;170:887-91.
Khalaf MA, Abbas MF, El-Fakahany HM. Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats. Andrologia. 2012;44(Suppl 1):370-5.
Eid AA, Badr El Dine FM, Nabil IM. Histopathologic and ultrastructural changes in seminiferous tubules of adult male albino rats following daily administration of different doses of tadalafil. Urology. 2016;90:89-96.
Jarvi K, Dula E, Drehobl M, Pryor J, Shapiro J, Seger M. Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with normal baseline levels. J Urol. 2008;179:1060-5.
Burger M, Sikka SC, Bivalacqua TJ, Lamb DJ, Hellstrom WJ. The effect of sildenafil on human sperm motion and function from normal and infertile men. Int J Impot Res. 2000;12:229-34.
Andrade JR, Traboulsi A, Hussain A, Dubin NH. In vitro effects of sildenafil and phentolamine, drugs used for erectile dysfunction, on human sperm motility. Am J Obstet Gynecol. 2000;182:1093-5.
Mostafa T. In vitro sildenafil citrate use as a sperm motility stimulant. Fertil Steril. 2007;88:994-6.
Lefievre L, De Lamirande E, Gagnon C. The cyclic GMP-specific phosphodiesterase inhibitor, sildenafil, stimulates human sperm motility and capacitation but not acrosome reaction. J Androl. 2000;21:929-37.
Cuadra DL, Chan PJ, Patton WC, Stewart SC, King A. Type 5 phosphodiesterase regulation of human sperm motility. Am J Obstet Gynecol. 2000;182:1013-5.
Mostafa T. Tadalafil as an in vitro sperm motility stimulant. Andrologia. 2007;39:12-5.
Biel M, Sautter A, Ludwig A, Hofmann F, Zong X. Cyclic nucleotide-gated channels-mediators of NO:cGMP-regulated processes. Naunyn Schmiedebergs Arch Pharmacol. 1998;358:140-4.
Glenn DR, McVicar CM, McClure N, Lewis SE. Sildenafil citrate improves sperm motility but causes a premature acrosome reaction in vitro. Fertil Steril. 2007;87:1064-70.
Ioki S, Wu QS, Takayama O, Motohashi HH, Wakai T, Funahashi H. A phosphodiesterase type-5 inhibitor, sildenafil, induces sperm capacitation and penetration into porcine oocytes in a chemically defined medium. Theriogenology. 2016;85:428-33.
Tur-Kaspa I, Segal S, Moffa F, Massobrio M, Meltzer S. Viagra for temporary erectile dysfunction during treatments with assisted reproductive technologies. Hum Reprod. 1999;14:1783-4.